Compare Stocks → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EPIXNASDAQ:EVLONASDAQ:KALVNASDAQ:LRMRNASDAQ:NXTC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPIXESSA Pharma$6.25-2.3%$8.39$2.56▼$11.67$283.14M1.62136,534 shs41,308 shsEVLOEvelo Biosciences$0.04$0.05$0.03▼$13.93$839K2.0341,315 shs1,279 shsKALVKalVista Pharmaceuticals$10.35-7.7%$12.53$7.21▼$16.88$472.93M0.88729,681 shs482,316 shsLRMRLarimar Therapeutics$6.46$9.01$2.18▼$13.68$412.15M0.93557,455 shs222,439 shsNXTCNextCure$1.44-5.9%$1.74$0.98▼$2.57$40.18M0.4234,413 shs176,635 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPIXESSA Pharma-2.34%-11.60%-30.86%-8.09%+133.21%EVLOEvelo Biosciences+4.00%+0.57%-11.60%-35.85%-98.52%KALVKalVista Pharmaceuticals-7.67%-11.16%-7.01%-19.46%+28.57%LRMRLarimar Therapeutics0.00%-8.37%-14.78%+36.58%+43.24%NXTCNextCure-5.88%-4.64%-27.64%+21.01%-5.26%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPIXESSA Pharma1.9839 of 5 stars3.54.00.00.00.03.30.0EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals4.0854 of 5 stars3.51.00.04.63.22.50.6LRMRLarimar Therapeutics2.1757 of 5 stars4.51.00.00.00.63.30.0NXTCNextCure3.923 of 5 stars3.53.00.04.60.01.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPIXESSA Pharma3.00Buy$16.50164.00% UpsideEVLOEvelo Biosciences2.00HoldN/AN/AKALVKalVista Pharmaceuticals3.00Buy$26.33154.43% UpsideLRMRLarimar Therapeutics3.00Buy$18.50186.38% UpsideNXTCNextCure3.00Buy$6.00316.67% UpsideCurrent Analyst RatingsLatest NXTC, LRMR, KALV, EVLO, and EPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/3/2024LRMRLarimar TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/3/2024LRMRLarimar TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$25.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/15/2024LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$25.002/20/2024LRMRLarimar TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.002/13/2024LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $10.002/13/2024LRMRLarimar TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$17.00 ➝ $25.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/AEVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/ANXTCNextCureN/AN/AN/AN/A$4.10 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)EVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)LRMRLarimar Therapeutics-$36.95M-$0.85N/AN/AN/AN/A-38.83%-34.33%5/20/2024 (Estimated)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)Latest NXTC, LRMR, KALV, EVLO, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A3/14/2024Q4 2023LRMRLarimar Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/A3/11/2024Q3 2024KALVKalVista Pharmaceuticals-$0.75-$0.84-$0.09-$0.84N/AN/A2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPIXESSA PharmaN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPIXESSA PharmaN/A40.7440.74EVLOEvelo BiosciencesN/A0.480.48KALVKalVista PharmaceuticalsN/A5.445.44LRMRLarimar TherapeuticsN/A9.499.49NXTCNextCureN/A16.3816.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPIXESSA Pharma75.12%EVLOEvelo Biosciences0.31%KALVKalVista PharmaceuticalsN/ALRMRLarimar Therapeutics91.92%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipEPIXESSA Pharma14.70%EVLOEvelo Biosciences1.02%KALVKalVista Pharmaceuticals12.30%LRMRLarimar Therapeutics4.30%NXTCNextCure11.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableLRMRLarimar Therapeutics4263.80 million61.06 millionOptionableNXTCNextCure8227.90 million24.58 millionOptionableNXTC, LRMR, KALV, EVLO, and EPIX HeadlinesSourceHeadlineNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024globenewswire.com - April 24 at 4:05 PMPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Ratingmarkets.businessinsider.com - April 8 at 7:06 PMNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024globenewswire.com - April 8 at 7:00 AMNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Boardglobenewswire.com - April 4 at 7:05 AMNextCure to Present at 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:00 AMNextCure, Inc. (NASDAQ:NXTC) Short Interest Updatemarketbeat.com - March 27 at 10:15 PMWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?finance.yahoo.com - March 27 at 10:07 AMWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Richinvestorplace.com - March 23 at 6:00 AMPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy Ratingmarkets.businessinsider.com - March 22 at 5:19 PMAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)markets.businessinsider.com - March 21 at 9:15 PMNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug Candidatesmarketwatch.com - March 21 at 4:06 PMNextCure to lay off 37% of staff, dial back research plansbiopharmadive.com - March 21 at 4:06 PMMd. biopharma lays off staff, pauses manufacturing to preserve cashbizjournals.com - March 21 at 4:06 PMNextCure Provides Business Update and Reports Full Year 2023 Financial Resultsglobenewswire.com - March 21 at 8:55 AMNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advancesglobenewswire.com - March 5 at 8:05 AMNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disordersfinance.yahoo.com - January 18 at 6:56 PMNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and Datesbenzinga.com - December 28 at 3:49 PMHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishingfinance.yahoo.com - December 25 at 2:02 PMNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injuryfinance.yahoo.com - December 21 at 7:59 AMNextCure (NXTC) Down on Shelving Plans to Develop Candidatefinance.yahoo.com - December 15 at 1:35 PMBuy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline Shiftmarkets.businessinsider.com - December 15 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)markets.businessinsider.com - December 15 at 12:33 AMNextCure stock falls 20% amid program shutdown, business updatemsn.com - December 14 at 7:32 PMNextCure Shares Fall 26% After Halting Development of One Drug Candidatemarketwatch.com - December 14 at 9:31 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Larimar TherapeuticsNASDAQ:LRMRLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.